Abstract
Relapsed and refractory (r/r) T-cell lymphoblastic lymphoma (T-LBL) is a highly lethal disease, with no effective treatment options. Daratumumab, an anti-CD38 human IgG1κ monoclonal antibody has been used as single agent in CD38 positive r/r T-LBL. We administered a salvage treatment with daratumumab in combination with bortezomib and dexamethasone regimen followed by allogeneic stem cell transplantation from HLA-haploidentical related donor in a 50 years old patient affected by cortical CD38 positive T-LBL, refractory to 2 prior therapies including first-line cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone (hyper-CVAD) regimen plus autologous stem cell transplantation. After 29 months he is alive and in sustained complete remission, emphasizing the role of daratumumab in combination with bortezomib and dexamethasone as a salvage treatment option in CD38 positive r/r T-LBL patients.